Shares of Hims & Hers Health Inc. (HIMS) surged 5.11% in Monday's pre-market session, following positive analyst coverage and raised price targets from Piper Sandler.
Analysts at Piper Sandler maintained a "Hold" rating on Hims & Hers Health but raised their price target on the stock from $21 to $24, reflecting potential growth opportunities for the company in the beauty and wellness sector.
While the firm highlighted interest rates, lending standards, and potential policies from the incoming administration as key factors to watch, it expressed optimism for U.S. beauty and wellness companies in 2025, positioning Hims & Hers Health as one of its top ideas for the year.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。